ARTICLE | Clinical News
Strongbridge's Cushing syndrome candidate meets in Phase III
August 10, 2018 6:29 PM UTC
Strongbridge Biopharma plc (NASDAQ:SBBP) said Recorlev levoketoconazole met the primary and secondary endpoints in the Phase III SONICS trial to treat endogenous Cushing syndrome.
On the 94-patient trial's primary endpoint, 30% of patients achieved normalization of mean urinary free cortisol (UFC) levels following six months of maintenance treatment with Recorlev without a dose increase (one-sided vs. a null hypothesis of a 20% or lower rate, p<0.025)...